HOME >> BIOLOGY >> NEWS
Biomedicines presents promising results from phase II trials of omega interferon for the treatment of hepatitis C

tectable in blood despite treatment with alpha interferon. Within 48 hours of the initiation of treatment with omega interferon, HCV RNA fell sharply in all patients, and in some to undetectable levels.

Chief Executive Officer Dr. Mark Moran said, "We are pleased with these results. We believe they also support our new drug delivery efforts with this drug. In collaboration with ALZA, we are also putting omega interferon into the implantable DUROS delivery system. With DUROS, we hope to be able to deliver omega interferon for months with a single administration.

Hepatitis C infection can lead to severe impairment of liver function, liver fibrosis, and liver cancer. According to the U.S. Center for Disease Control, HCV infects nearly 3 million people in the United States, and the World Health Organization estimates 170 million people are infected worldwide. Many infected persons are unaware of the infection. The spread of HCV infection has reached epidemic proportions, as some experts believe that without substantial improvements in treatment, the death toll from HCV infection will surpass that from HIV.


'"/>

Contact: Emily Katz
e.katz@noonanrusso.com
415-677-4455
Noonan/Russo Communications
12-Nov-2001


Page: 1 2

Related biology news :

1. DFG presents the 2004 MAK and BAT value lists
2. VIB presents its annual results at BIO2004 in San Francisco
3. Steroid-coated DNA represents new approach to gene delivery
4. ASH presents advocacy awards to Sen. Dianne Feinstein and Claude Lenfant, M.D.
5. DFG presents the new MAK and BAT Value List 2003
6. Center for Health Law and Policy presents program on bioterrorism measures and civil liberties
7. Agriculture presents common ground for rural, urban people
8. UPCI presents study on estrogenic activity of medicinal botanicals
9. UPCI presents study on dendritic cells in prostate cancer
10. UPCI presents study on discovery of protein that suppresses dendritic cells
11. USF presents new research on hyperlipidemic children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
Cached News: